DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for panhypopituitarism, X-linked — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePanhypopituitarism, X-linked maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for panhypopituitarism, x-linked is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 27-year-old woman with panhypopituitarism from a suprasellar germinoma, including diabetes insipidus, hypothyroidism, adrenal cortex dysfunction, and hypogonadotropic ovarian failure, conceived and delivered healthy twins after treatment with thyroxin, cortisol, antidiuretic hormone, human menopausal gonadotropin, and human chorionic gonadotropin. An 8-month-old child with panhypopituitarism was found to carry a novel homozygous HESX1 mutation (R160H) within the homeodomain, the first such mutation described in humans. Neuroimaging showed anterior pituitary aplasia, a normal posterior pituitary, and a thin pituitary stalk but no midline abnormalities or optic nerve pathology. The parents were heterozygous carriers, indicating autosomal recessive inheritance.
A 32-year-old man who had panhypopituitarism after craniopharyngioma resection at age 8 and self-interrupted hormone replacement at age 20 presented with decompensated cirrhosis and hepatopulmonary syndrome. Despite restarting hormone replacement and home oxygen, poorly controlled hypothalamic obesity led to liver failure, and he awaited liver transplantation. The report states that liver cirrhosis associated with long-term panhypopituitarism may have a poor prognosis even with hormone replacement therapy. A 55-year-old woman presented to an emergency department with weakness and was diagnosed with panhypopituitarism after workup; the report emphasises that vague complaints require careful history and examination to reach a definitive diagnosis.
A prepubertal woman with growth retardation and combined pituitary hormone deficiency (central hypopituitarism, hypogonadism, growth hormone deficiency) caused by a homozygous PROP1 mutation (c.150delA) was diagnosed in young adulthood due to unfavourable life circumstances. With cautiously combined growth hormone therapy and sex hormone therapy, she achieved better than expected height (exceeding predictions based on family height) and sexual maturation including regular menstrual cycles. The report states that early diagnosis is essential for successful treatment but that carefully titrated therapy initiated in adulthood can still enable restoration of physiological growth and sexual development.
What is missing is prospective data on long-term outcomes in panhypopituitarism, particularly for liver disease and metabolic complications, and systematic trials of hormone replacement regimens in adults diagnosed late. Patient stratification by genetic cause (HESX1, PROP1, or acquired lesions) and by adherence to therapy is not yet standardised, and funding for such natural history studies remains scarce.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 2003 · 15 citations
Successful twin pregnancy in panhypopituitarism caused by suprasellar germinoma
AbstractBACKGROUND: Pregnancy in a woman with hypopituitarism from a suprasellar germinoma is rare. CASE: A 27-year-old woman presented with panhypopituitarism from a suprasellar germinoma. She had diabetes insipidus, hypothyroidism, adrenal cortex dysfunction, and hypogonadotropic ovarian failure. When treated with thyroxin, cortisol, antidiuretic hormone, human menopausal gonadotropin, and human chorionic gonadotropin, she conceived and gave birth to healthy twins. CONCLUSION: Hormonal replacement therapy and ovulation induction resulted in a successful pregnancy in a woman with panhypopituitarism.
AbstractAcromegaly is a disabling and often fatal disease. As it is usually caused by a pituitary tumour, its manifestations should be arrested by removal of the tumour. Earlier surgical treatment has seldom produced lasting improvement, since radical removal has not been done, partly to avoid the appearance of panhypopituitarism. Modern substitution therapy now makes it possible to perform total hypophysectomy.An account is given of 13 cases of acromegaly in which total hypophysectomy was performed with the transantrosphenoidal technique devised by the authors. Excellent results were obtained in the 12 cases in which removal of the tumour was radical. No signs of reactivations have been observed during a follow-up period ranging from 3 months to 4 1/2 years. Any existing hormonal insufficiency has been controlled by substitution therapy.
Journal of Pediatric Endocrinology and Metabolism · 2011 · 11 citations
A novel homozygous HESX1 mutation causes panhypopituitarism without midline defects and optic nerve anomalies
AbstractOBJECTIVE: There are many genes reported to have been associated with combined pituitary hormone deficiencies, but mutations in HESX1 strongly correlate with septo-optic dysplasia. Our aim was to determine the cause of panhypopituitarism in our patient. PATIENTS AND METHODS: We studied an 8-month-old child having panhypopituitarism. The coding exons of PIT1, PROP1, LHX3, and HESX1 genes were amplified. Direct sequencing was done after denaturing HLPC. RESULTS: We identified a novel homozygous mutation (R160H) within the homeodomain of HESX1, which, to our knowledge, is the first to be described in humans. Neuroimaging studies revealed anterior pituitary aplasia, a normal posterior pituitary gland, and a thin pituitary stalk but no midline abnormalities. Optic nerve studies showed no pathology. This mutation is also carried in the parents of the affected child in a heterozygous pattern, suggesting an autosomal recessive inheritance. CONCLUSION: These data demonstrate that homozygous HESX1 mutation causing an R160H substitution can result in panhypopituitarism without midline defects.
Internal Medicine · 2025 · 3 citations · open access
Decompensated Cirrhosis with Hepatopulmonary Syndrome in a Patient with Interrupted Treatment for Hypopituitarism
AbstractA 32-year-old man presented with cirrhosis. At 8 years of age, he underwent resection of a craniopharyngioma, which resulted in panhypopituitarism. He underwent self-interrupted hormone replacement therapy at 20 years of age. Computed tomography revealed severe fatty liver and cirrhosis. An endocrinological evaluation revealed panhypopituitarism. Further assessment revealed a diagnosis of hepatopulmonary syndrome. Home oxygen therapy and hormone replacement therapy were initiated. Despite these efforts, poorly controlled hypothalamic obesity led to liver failure, and the patient is currently awaiting liver transplantation. Liver cirrhosis associated with long-term panhypopituitarism may have a poor prognosis even with hormone replacement therapy.
Emergency Medicine Open Access · 2014 · 1 citations
A Case Report of Panhypopituitarism with Atypical Manifestation
AbstractBackground
The panhypopituitarism is a rare endocrine system disease; the clinical presentation of a panhypopituitarism patient can vary from asymptomatic or subclinical cases to life-threatening myxedema coma.
Case report
Our patient is a 55 years old woman who was presented to emergency department with chief complains of weakness. After necessary workup, panhypopituitarism was diagnosed.
Discussion
There are different diagnoses for weakness. In patients with vague complaints such as weakness, we should take their history carefully and perform clinical examinations to reach a definitive diagnosis.
Frontiers in Endocrinology · 2017 · 1 citations · open access
Therapy-Induced Growth and Sexual Maturation in a Developmentally Infantile Adult Patient with a PROP1 Mutation
AbstractBACKGROUND: Hypopituitarism as a result of PROP1 (prophet of PIT1) mutation represents the most common genetic cause of combined deficiency of pituitary hormones and due to growth retardation it is typically diagnosed in childhood. CASE DESCRIPTION: We present a unique case report of a prepubertal woman with growth retardation in whom combined pituitary hormone deficiency [central hypopituitarism, hypogonadism, and growth hormone (GH) deficiency] caused by homozygous mutation c.150delA in the PROP1 gene was diagnosed late in young adulthood due to unfavorable life circumstances. Through cautiously combined GH therapy and sex hormone therapy, she has achieved better than expected height (exceeding predictions based on family height) and sexual maturation, including regular menstrual cycles. CONCLUSION: Early diagnosis of panhypopituitarism due to PROP1 mutation is essential for successful treatment; however, our case report shows that carefully titrated GH treatment and sex hormone substitution, although initiated in adulthood, enable restoration of physiological growth and sexual development in a hormonally infantile adult woman with a PROP1 mutation.
Panhypopituitarism Due to a Pituitary Macroadenoma
AbstractPanhypopituitarism, particularly secondary hypothyroidism and adrenal insufficiency, is a rare cause of cardiac tamponade. Recognition of this association and proper hormonal replacement are paramount to effective therapy for this cardiac emergency. We present the clinical course of a patient whose cardiac tamponade was of a pituitary etiology. Relevant medical literature is also reviewed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
